Patients Remain Undetectable 96 Weeks After Stopping Bulevirtide
A study found that 90% of hepatitis D patients who were undetectable for 96 weeks before stopping bulevirtide remained undetectable for 2 years off therapy. Bulevirtide, approved in several countries, is the first treatment for hepatitis D. The study, sponsored by Gilead Sciences, suggests that stopping the drug can lead to relapses and liver enzyme flares, particularly in patients with cirrhosis.
How this was made
The 30-second read
Why it matters
The data suggest a clear relationship between duration of undetectable HDV RNA before stopping and sustained response, providing a potential stopping rule for clinicians.
Market read
New efficacy data could lift Gilead's valuation and influence hepatitis D treatment landscape.
What to watch
Potential safety concerns with ALT flares post‑stop and need for long‑term monitoring may temper enthusiasm.
Background
Bulevirtide, the first‑in‑class entry inhibitor for hepatitis D, is approved in multiple regions. The trial examined off‑treatment durability, a key unanswered question for payers and clinicians.
Ticker impact
Phase III trial data for bulevirtide shows 90% durability when undetectable ≥96 weeks, a new efficacy benchmark for the drug.
likely upside as investors price in stronger market potential for bulevirtide.
First report of durable off‑treatment response; data are favorable and could drive future sales expectations.
Market effects
strengthens biotech focus on hepatitis D treatments and may spur competitor R&D.
U.S. and European markets could see modest gains in biotech indices.
global hepatitis D patient pool relevance, but limited immediate macro impact.
Counterpoint
Durability data are based on small sub‑cohort; real‑world adherence and payer coverage could limit upside.
Key entities
- CompanyGilead Sciences
Sponsor of the bulevirtide trial and holder of the drug's commercial rights.
- DrugBulevirtide
First‑in‑class hepatitis D entry inhibitor.
